University of Nizwa College of Pharmacy and Nursing School of Pharmacy

Slides:



Advertisements
Similar presentations
Kidney Physiology Kidney Functions: activate vitamin D (renal 1-alpha hydroxylase)activate vitamin D (renal 1-alpha hydroxylase) produces erythropoietin.
Advertisements

Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Protein-, Mineral- & Fluid-Modified Diets for Kidney Diseases
End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.
Chronic Renal Failure (End Stage Renal Disease “ESRD”) Dr. Belal Hijji, RN, PhD April 18 & 23, 2012.
Critical Care Nursing A Holistic Approach Part 6.
Renal Megan McClintock, RN, MS 10/27/11 “TO PEE IS TO LIVE”
Elsevier items and derived items © 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc. Chapter 71 Care of Patients with Acute Renal Failure and Chronic.
Chronic Kidney Disease
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Finishing Renal Disease Aging and death. Chronic Renal Failure Results from irreversible, progressive injury to the kidney. Characterized by increased.
Adult Medical-Surgical Nursing Renal Module: Acute Renal Failure.
RENAL DISEASE CAITLIN MCFARLAND JENNIFER SEEGERS RICKY TURNER.
Diseases of the Urinary System
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
CHRONIC RENAL FAILURE JAKUB ZÁVADA KLINIKA NEFROLOGIE 1.LF UK.
Nutrition for Patients with Kidney Disorders Chapter 21
Disorders of the Urinary System
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
Diabetic Ketoacidosis DKA)
Peritoneal Dialysis End Stage Renal Disease Causes and Treatment Methods.
Essential Questions  What are the functions of the urinary system?  What are some disorders of the urinary system?  How are disorders of the urinary.
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Aminoglycoside-Induced Acute Tubular Necrosis PHCL 442 Lab Discussion 2 Raniah Al-Jaizani M.Sc.
RENAL FAILURE The term Renal Failure means failure of renal excretory function due to depression of GFR. ACUTE RENAL FAILURE Acute renal failure (ARF)
Renal Disease Normal Anatomy andPhysiology. Renal: Normal Anatomy 1. Renal artery and vein: 25% of blood volume passes through the kidney / minute 2.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
Renal Disease  Kidney functions  The nephrotic syndrome  Acute Renal Disease  Chronic Renal Failure  Kidney Stones.
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Acute Renal Failure Doç. Dr. Mehmet Cansev. Acute Renal Failure Acute renal failure (ARF) is the rapid breakdown of renal (kidney) function that occurs.
Renal Pathophysiology III : Diseases that affect the kidney and urinary tract Acute and chronic renal failure.
Diseases and disorders
CHRONIC KIDNEY DISEASE
Chapter 37 Chronic Kidney Disease: The New Epidemic
Diabetes And Hemodialysis 1 Dr.Ruba Nashawati. 2.
J Winterbottom 2005 Chronic Renal Failure (CRF) (End stage renal disease ) (ESRD)
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 42 Acute Renal Injury and Chronic Kidney Disease.
Gilead -Topics in Human Pathophysiology Fall 2009 Drug Safety and Public Health.
Nursing management of Acute Kidney Injury
Drugs for Hypertension
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
Renal failure  It implies destruction of nephrons and failure of the kidney to maintain hemostasis (failure to excrete waste products or regulate water.
Acute and Chronic Renal Failure
Darshika Chhabra, MD, MPH
Renal disorders.
Chronic renal failure.
Hypertension JNC VIII Guidelines.
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Presented By Dr / Said Said Elshama
Chronic Renal Failure (End Stage Renal Disease “ESRD”)
presentation: nephrotic syndrome
Kidney Function Tests.
Written By: Sarah Gobbell
Urinary System Function, Assessment, and Therapeutic Measures
Diabetes Health Status Report
Pathophysiology of Renal System
URINARY SYSTEM DISEASES
6/18/2018 Intensive Care; Acute Renal Failure 1 Continuous Renal Replacement Therapy (CRRT) Maureen Walter,Raquel Lomeli Anika Stevenson,Nellie Preble.
Acute and Chronic Renal Failure
Renal Disease Filtration, glomeruli generate removal ultrafiltrate of the plasma based on size and charge of molecules End products include urea, creatinine,
Dialysis Options: What is the Best Choice for You. Ana C
Diuretics, Kidney Diseases Urine R&M
The Urinary System Lesson 2: Pathology of the Urinary System
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Clinical Pharmacokinetics
Note.
Presentation transcript:

University of Nizwa College of Pharmacy and Nursing School of Pharmacy PHARMACOTHERAPY - I PHCY 310 Lecture -15 “Renal Failure” Dr. Sabin Thomas, M. Pharm. Ph. D. Assistant Professor in Pharmacy Practice School of Pharmacy University of Nizwa

Course Outcome Upon completion of this lecture the students will be able to Define and classify acute and chronic renal failures, and its clinical signs and symptoms, Describe the pathogenesis of both acute and chronic renal failure and its management strategies, Recommend the treatment for patients with acute and chronic renal failure.

Acute Renal Failure Defined as a decrease in glomerular filtration rate (GFR) occurring over hours to weeks that is associated with an accumulation of waste products, including urea and creatinine. ARF should be suspected when the kidney is unable to regulate fluid, electrolyte, acid–base, or nitrogen balance, even in the presence of a normal SrCr concentration. Clinicians use a combination of the serum creatinine (Scr) value with change in either Scr or urine output (UOP) as the primary criteria for diagnosing ARF

Clinical Presentation Oliguric Phase- Urine production of <400 mL/day is termed oliguria, and urine production of <50 mL/day is termed anuria. The oliguric stage may last from days to several weeks. After the oliguric phase, a period of increased urine production occurs over several days; this is called the diuretic phase. The recovery phase occurs over several weeks to months, depending on the severity of the patient's ARF. Symptoms in the outpatient setting include change in urinary habits,weight gain, or flank pain. Signs include edema, colored or foamy urine, and, in volume-depleted patients, orthostatic hypotension.

Pathogenesis ARF can be categorized as prerenal (resulting from decreased renal perfusion), intrinsic (resulting from structural damage to the kidney), postrenal (resulting from obstruction of urine flow from the renal tubule to the urethra), functional (resulting from hemodynamic changes at the glomerulus independent of decreased perfusion or structural damage)

DIAGNOSIS Thorough medical and medication histories, physical examination, assessment of laboratory values and if needed, imaging studies, are important in the diagnosis of ARF. Scr and blood urea nitrogen cannot be used alone to diagnose ARF because they are insensitive to rapid changes in GFR and therefore may not reflect current renal function. Monitoring changes in Urinary Output (UOP) can help diagnose the cause of ARF.

PREVENTION OF ACUTE RENAL FAILURE TREATMENT PREVENTION OF ACUTE RENAL FAILURE Risk factors for ARF include advanced age, acute infection, preexisting chronic respiratory or cardiovascular disease, dehydration, and chronic kidney disease (CKD). Decreased renal perfusion secondary to abdominal or coronary bypass surgery, acute blood loss in trauma, and uric acid nephropathy also increase risk.

Non-pharmacologic Approaches No drugs have been found to accelerate ARF recovery. Supportive care goals include maintenance of adequate cardiac output and blood pressure to optimize tissue perfusion while restoring renal function to pre-ARF baseline. Medications associated with diminished renal blood flow should be stopped. Appropriate fluid replacement should be initiated. Avoidance of nephrotoxins is essential in the management of patients with ARF. Renal replacement therapy (RRT), such as hemodialysis and peritoneal dialysis, maintains fluid and electrolyte balance while removing waste products.

Pharmacologic Approaches The most effective diuretics are mannitol and loop diuretics. Mannitol 20% is typically started at a dose of 12.5 to 25 g IV over 3 to 5 minutes. Disadvantages include IV administration, hyperosmolality risk,and need for monitoring because mannitol can contribute to ARF. Equipotent doses of loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid) have similar efficacy.

Ethacrynic acid is reserved for sulfa allergic patients. Continuous infusions of loop diuretics appear to be more effective and to have fewer adverse effects than intermittent boluses. An initial IV loading dose (equivalent to furosemide 40 to 80 mg) should be administered before starting a continuous infusion (equivalent to furosemide 10 to 20 mg/hour).

ELECTROLYTE MANAGEMENT AND NUTRITION THERAPY Hyperkalemia is the most common and serious electrolyte abnormality in ARF. Typically, potassium must be restricted to less than 3 g/day and monitored daily. Hypernatremia and fluid retention commonly occur, necessitating restricting daily sodium intake no more than 3 g. All sources of sodium, including antibiotics, need to be considered when calculating daily sodium intake. Phosphorus and magnesium should be monitored; neither is efficiently removed by dialysis. Enteral, but not parenteral, nutrition has been shown to improve patient outcomes.

Chronic Kidney Disease A progressive loss of function over several months to years, characterized by gradual replacement of normal kidney architecture with interstitial fibrosis. It is categorized by the level of kidney function, based on glomerular filtration rate (GFR), into stages 1 to 5, with each increasing number indicating a more advanced stage of the disease, as defined by a declining GFR. CKD stage 5, previously referred to as end-stage renal disease (ESRD), occurs when the GFR falls below 15 mL/min per 1.73 m2 body surface area. The patient with stage 5 CKD requiring chronic dialysis or renal transplantation for relief of uremic symptoms is said to have ESRD.

PATHOPHYSIOLOGY Susceptibility factors increase the risk for kidney diseaseinclude advanced age, reduced kidney mass and low birth weight, racial or ethnic minority, family history, low income or education, systemic inflammation, and dyslipidemia. Initiation factors include diabetes mellitus, hypertension, autoimmune disease, polycystic kidney disease, and drug toxicity. Progression factors include glycemia in diabetics, hypertension, proteinuria, and smoking.

CLINICAL PRESENTATION Patients with stage 1 or 2 CKD usually do not have symptoms or metabolic derangements. It is seen with stages 3 to 5, such as anemia (decreased production of erythropoietin), secondary hyperparathyroidism, cardiovascular disease, malnutrition, and fluid and electrolyte abnormalities that are more common as kidney function deteriorates. Uremic symptoms (fatigue, weakness, shortness of breath, mental confusion, nausea, vomiting, bleeding, and anorexia) are generally absent in stages 1 and 2, It is minimal during stages 3 and 4, and common in patients with stage 5 CKD who may also experience itching, cold intolerance, weight gain, and peripheral neuropathies.

NONPHARMACOLOGIC THERAPY A low-protein diet (0.6 to 0.75 g/kg/day) can delay progression of CKD in patients with or without diabetes, although the benefit is relatively small.

PHARMACOLOGIC THERAPY Hyperglycemia Intensive therapy in patients with type 1 and type 2 diabetes reduces microvascular complications, including nephropathy. Intensive therapy can include insulin or oral drugs and involves blood sugar testing at least three times daily. The progression of CKD can be limited by optimal control of hyperglycemia and hypertension.

Hypertension Adequate blood pressure control can reduce the rate of decline in GFR and albuminuria in patients with or without diabetes. Antihypertensive therapy should be initiated in diabetic or nondiabetic CKD patients with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker. Nondihydropyridine calcium channel blockers are generally used as second-line antiproteinuric drugs when ACEIs or angiotensin II receptor blockers are not tolerated.

Supportive Therapies Dietary protein restriction lipid-lowering medications, smoking cessation, and anemia management (Erythropoiesis stimulating agent [ESA] therapy) may help slow the rate of CKD progression. The primary goal of lipid-lowering therapies in CKD is to decrease the risk for progressive atherosclerotic cardiovascular disease. A secondary goal is to reduce proteinuria and renal function decline seen with administration of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors).